Accepted for/Published in: JMIR Formative Research
Date Submitted: Dec 16, 2024
Date Accepted: Feb 20, 2025
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
A Smartphone App to Increase Pre-Transplant Vaccine Rates: Assessing Feasibility, Acceptability, and Effectiveness
ABSTRACT
Background:
Background:
Vaccine preventable infections result in significant morbidity, mortality and costs in pediatric transplant recipients. Despite intensive medical care in the pre-transplant period, less than 20% of children are up to date for age-appropriate vaccines at the time of transplant. Mobile health apps have the potential to improve pre-transplant vaccine rates.
Objective:
Objectives: To perform Phase 2 beta-testing of the smartphone app, Immunize PediatricTransplant, to determine 1) if it was effective in achieving up to date vaccine status by the time of transplant in a cohort of children awaiting transplant and 2) if the app was feasible and acceptable to parent and transplant provider users.
Methods:
Methods:
We recruited 25 dyads of parents and providers of a child awaiting liver, kidney, or heart transplant at Children’s Hospital Colorado, Lurie Children’s Hospital, and the Children’s Hospital of Philadelphia. Parents and providers filled out an Entry Questionnaire before app use to gather baseline information. A research team member entered the child’s vaccine records into the app. The parent and provider downloaded and used the app until transplant to view vaccine records, read vaccine education, communicate with team members, and receive overdue vaccine reminders. After transplant (or on 4/1/2024, the conclusion of the study), the parent and provider filled out an Exit Questionnaire to explore feasibility and acceptability of the app. The child’s vaccine records were reviewed to determine if the child was up to date on vaccines at transplant.
Results:
Results:
Twenty-five parent/provider dyads were enrolled; 56% (14/25) of a child awaiting liver, 28% (7/25) kidney, and 16% (4/25) heart transplant. At the conclusion of the study, 96% (24/25) of the children were up to date on vaccines. Of the 36 parents and providers who filled out an Exit Questionnaire, 97% (35/36) agreed/strongly agreed that they felt knowledgeable about pre-transplant vaccine use and 86% (31/36) agreed/strongly agreed that communication around vaccines was good after using the app. Ninety-one percent (20/22) of parents and 79 percent (11/14) of providers recommended the app to future parents and providers of transplant candidates. Parents and providers suggested that in the future the app connect directly to the electronic medical record or state vaccine registries to obtain vaccine data.
Conclusions:
Conclusions:
The overwhelming majority of children whose parents and providers used the Immunize PediatricTransplant app were up to date on vaccines at the time of transplant. The majority of app users felt the app was feasible and acceptable. In future iterations of the app and subsequent clinical trials, we will explore whether application programming interfaces might be used to extract vaccine data from the electronic medical record. If implemented broadly, this app has the potential to improve pre-transplant vaccine rates, resulting in fewer post-transplant infections and improved post-transplant outcomes. Clinical Trial: n/a
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.